What is Dipeptidyl Peptidase?
Dipeptidyl peptidases (DPPs) are a group of enzymes that belong to the serine protease family, specialized in cleaving dipeptides from the N-terminal end of polypeptides. They are crucial in regulating the activity of many bioactive peptides, including hormones, chemokines, and growth factors. By controlling peptide processing, DPPs help maintain metabolic balance, immune regulation, and cellular signaling.
Role as Serine Proteases
As serine proteases, dipeptidyl peptidases use a catalytic triad — typically composed of serine, histidine, and aspartate — to break peptide bonds. This enzymatic mechanism enables them to target peptides with a proline or alanine residue in the penultimate position, making them highly specific compared to other proteases. Their activity is essential for the degradation or inactivation of regulatory peptides in various physiological pathways.
Types of Dipeptidyl Peptidases
Several members of the DPP family have been identified, each with distinct biological roles:
- DPP-4 (Dipeptidyl Peptidase-4): The most widely studied member, known for inactivating incretin hormones such as GLP-1 and GIP, which are vital for glucose metabolism. It is a key therapeutic target in type 2 diabetes.
- DPP-8 and DPP-9: Less characterized but play roles in immune regulation, cell survival, and inflammatory processes. Their inhibition has been linked to potential side effects, which makes them less explored as drug targets.
- FAP (Fibroblast Activation Protein): Expressed in cancer-associated fibroblasts and involved in tissue remodeling, fibrosis, and tumor progression.
Together, these enzymes form a multifunctional family that connects metabolic regulation, immunity, and disease progression, making them highly relevant in both biology and medicine.
Structure and Enzymatic Mechanism of Dipeptidyl Peptidases
Dipeptidyl peptidases (DPPs) share structural and functional features characteristic of the serine protease family, but they also exhibit unique properties that make them highly selective in peptide cleavage. Understanding their structure and enzymatic mechanism is essential to explain how they regulate biological processes and why they are attractive drug targets.
Structural Features
Most dipeptidyl peptidases are type II transmembrane glycoproteins, meaning they are anchored to the cell membrane but can also exist in soluble forms. They are typically composed of:
- Cytoplasmic tail: A short intracellular domain that anchors the enzyme.
- Transmembrane region: A hydrophobic segment that spans the cell membrane.
- Extracellular catalytic domain: Contains the catalytic triad (serine, histidine, and aspartate) responsible for enzymatic activity.
For example, DPP-4 exists both as a membrane-bound protein and in a soluble circulating form. The membrane-bound enzyme is expressed on various cell types, including endothelial cells, T lymphocytes, and epithelial cells, highlighting its multifunctional roles in metabolism and immunity.
Enzymatic Mechanism
Dipeptidyl peptidases function by cleaving dipeptides from the N-terminal end of polypeptides. Their substrate specificity is unique — they preferentially remove dipeptides when the penultimate (second) amino acid is a proline or alanine. This makes them key regulators of proline-containing peptides, such as incretin hormones.
The catalytic mechanism involves:
- Substrate recognition – The enzyme recognizes peptides with the correct N-terminal sequence.
- Catalysis via the serine residue – The serine in the catalytic triad forms a covalent bond with the substrate.
- Peptide bond cleavage – Assisted by histidine and aspartate residues, the bond is hydrolyzed.
- Product release – A shortened peptide (or inactivated peptide) is released, ready for further degradation or clearance.
Biological Significance
Through this mechanism, DPPs exert control over hormones, chemokines, and growth factors, thereby influencing glucose metabolism, immune responses, and tissue remodeling. The high substrate specificity makes them attractive targets for designing selective inhibitors used in the treatment of type 2 diabetes and other metabolic diseases.
Biological Functions of Dipeptidyl Peptidases
Dipeptidyl peptidases (DPPs) play central roles in maintaining metabolic balance, immune regulation, and tissue remodeling. By selectively cleaving bioactive peptides, they influence a wide range of physiological processes.
Regulation of Incretin Hormones
One of the most studied functions of DPP-4 is the inactivation of incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). These hormones are secreted after meals and stimulate insulin release, helping to lower blood glucose levels.
- By rapidly degrading incretins, DPP-4 shortens their half-life to just a few minutes.
- This activity directly impacts glucose metabolism and explains why DPP-4 inhibitors are widely used in type 2 diabetes treatment.
Influence on Immune Regulation
Beyond metabolism, DPPs also modulate the immune system.
- DPP-4 (also known as CD26) is expressed on the surface of T lymphocytes and participates in T-cell activation, proliferation, and cytokine production.
- DPP-8 and DPP-9 have emerging roles in immune cell survival and inflammatory pathways. Dysregulation of these enzymes has been linked to autoimmune diseases and chronic inflammation.
Role in Protein and Peptide Degradation
DPPs help maintain protein turnover and peptide balance in the body by removing N-terminal dipeptides. This selective cleavage prevents the excessive buildup of regulatory peptides and ensures precise control of signaling pathways.
Contribution to Tissue Remodeling and Disease
Some DPP family members, such as fibroblast activation protein (FAP), contribute to tissue repair and remodeling.
- FAP is highly expressed in cancer-associated fibroblasts and fibrotic tissues.
- Its activity promotes extracellular matrix degradation, making it relevant in cancer progression, fibrosis, and wound healing.
Dipeptidyl Peptidase Inhibitors in Medicine
The discovery of dipeptidyl peptidase inhibitors, particularly those targeting DPP-4, has revolutionized the management of type 2 diabetes mellitus (T2DM). These drugs, commonly referred to as gliptins, work by preventing the rapid breakdown of incretin hormones, thereby enhancing the body’s natural ability to regulate blood glucose.
Mechanism of Action
DPP-4 inhibitors block the enzyme’s activity, which normally degrades GLP-1 and GIP. As a result:
- The half-life of incretin hormones is prolonged.
- Insulin secretion increases in a glucose-dependent manner.
- Glucagon secretion is suppressed, lowering hepatic glucose production.
- Overall, blood glucose levels are reduced without significant risk of hypoglycemia.
This mechanism makes DPP-4 inhibitors a safe and effective therapy for patients with T2DM, particularly those who require add-on therapy to metformin.
Examples of DPP-4 Inhibitors (Gliptins)
Several DPP-4 inhibitors are available and widely prescribed worldwide:
- Sitagliptin – one of the first approved and most commonly used.
- Saxagliptin – often used in combination therapies.
- Linagliptin – unique for its non-renal clearance, making it suitable for patients with kidney impairment.
- Alogliptin – effective as monotherapy or in combination.
- Vildagliptin – widely prescribed in Europe and Asia.
Clinical Benefits
- Improved glycemic control with modest reductions in HbA1c.
- Low risk of hypoglycemia, especially compared to sulfonylureas.
- Generally weight-neutral, unlike other antidiabetic drugs such as insulin or thiazolidinediones.
- Well tolerated with a favorable safety profile.
Limitations and Considerations
While effective, DPP-4 inhibitors are not without limitations:
- Their glucose-lowering effect is moderate compared to newer drug classes such as GLP-1 receptor agonists or SGLT2 inhibitors.
- Long-term cardiovascular outcomes remain an area of active research, with some studies suggesting mixed results.
- Rare adverse effects, including joint pain or increased risk of infections, have been reported.
Other Members of the DPP Family
While DPP-4 has received the most clinical attention, other members of the dipeptidyl peptidase family—DPP-8, DPP-9, and fibroblast activation protein (FAP)—are increasingly recognized for their roles in immunity, cancer, and tissue remodeling. These enzymes share structural similarities with DPP-4 but have distinct biological functions and therapeutic implications.
DPP-8 and DPP-9
- Both DPP-8 and DPP-9 are intracellular enzymes with overlapping functions in regulating immune responses, cell survival, and apoptosis.
- They have been implicated in inflammatory pathways, with abnormal activity linked to autoimmune disorders and chronic inflammation.
- However, inhibiting DPP-8 and DPP-9 has been associated with toxic side effects in preclinical models, including severe immune-related reactions. This toxicity limits their potential as therapeutic targets compared to DPP-4.
Fibroblast Activation Protein (FAP)
- FAP is a membrane-bound serine protease predominantly expressed in activated fibroblasts, particularly in the stroma of tumors, fibrotic tissues, and healing wounds.
- It contributes to extracellular matrix degradation, facilitating tissue remodeling.
- In cancer, FAP promotes tumor growth and metastasis by supporting the tumor microenvironment.
- As a result, FAP has become a promising biomarker and therapeutic target in oncology and fibrosis research, with experimental drugs and imaging tools under investigation.
Physiological and Clinical Significance
Although less explored than DPP-4, these enzymes highlight the diverse roles of the DPP family:
- DPP-8/9 → immune regulation and inflammation.
- FAP → tissue remodeling, fibrosis, and cancer progression.
Understanding these proteins may pave the way for novel therapeutic strategies beyond diabetes, including in autoimmune diseases, oncology, and regenerative medicine.
Conclusion
Dipeptidyl peptidases (DPPs) represent a diverse family of enzymes with critical roles in metabolism, immunity, and disease regulation. Among them, DPP-4 has gained the most attention due to its role in glucose metabolism and the development of DPP-4 inhibitors, now a cornerstone of type 2 diabetes therapy. Other family members, such as DPP-8, DPP-9, and FAP, are emerging as important players in inflammation, cancer, and tissue remodeling, expanding the clinical relevance of these enzymes. As research continues, targeting dipeptidyl peptidases holds promise not only for improving metabolic health but also for addressing a wide range of immune and oncological conditions.
